NIH Just Killed the Training Ground for Clinical Trialists. The Damage Will Take a Decade to See.
NIH's Program Update 3 eliminates Independent Clinical Trial Required K awards — 573 active K23s affected. The clinician-scientist pipeline...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trials CLINOPS WATCHDOG CNS Trials Conference Coverage CRO Consolidation Decentralized Clinical Trials Digital Health Technologies dual diagnosis eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
NIH's Program Update 3 eliminates Independent Clinical Trial Required K awards — 573 active K23s affected. The clinician-scientist pipeline...
EMA revoked Tavneos (avacopan) in August 2026 over GCP breaches in the pivotal ADVOCATE trial. FDA approved the same...
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...
Over 1,500 AI-enabled medical devices have FDA authorization, yet rigorous RCT validation trails far behind. Here's the mechanism breaking...
Phase II trial terminations rose to 31% in 2025, driven by site delays and participant dropout. WCG report reveals...
AbelZeta obtains FDA IND clearance for Prizlon-cel, a bispecific CAR-T therapy targeting CD20/CD19 in large B-cell lymphoma, backed by...
AI clinical trial decision support is a $1.35B market growing at 12.5% annually—but FDA's draft ML guidance and real-world...
Meant launches LegitScript-certified GLP-1 telehealth platform with coaching support and prescription services across all 50 states.
Skye Bioscience acquires Redx Pharma and exits obesity development to pivot toward fibrosis and oncology with $125M financing.
Aizen Therapeutics secured a multi-program collaboration worth up to $100M per target using AI-designed peptides for immunology and neurology...